No additional generic versions of Allergan’s Taytulla (norethindrone acetate/ethinyl capsules; ferrous fumarate capsules) will be approved before late July, after Slayback Pharma launched its AB-rated generic, Merzee, with an ‘effective’ 180-day market exclusivity period provided under the competitive generic therapy pathway.
Slayback clarified that its launch of the oral contraceptive will not impact the first generic version of Taytulla, Xiromed’s Gemmily,...




